Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19852920 | 0.86 | TSHR (0.42) | TSHRAPEX1BLMOPRM1OPRL1 | |
| SCHEMBL21233890 | 0.83 | TSHR (0.36) | TSHRAPEX1BLMOPRM1OPRL1 | |
| SCHEMBL23009671 | 0.80 | TSHR (0.35) | TSHRAPEX1BLMOPRM1OPRL1 | |
| SCHEMBL21238958 | 0.80 | TSHR (0.35) | TSHRAPEX1BLMOPRM1OPRL1 | |
| SCHEMBL17351894 | 0.79 | ELANE (0.42) | TSHRKMT2A | |
| SCHEMBL15937076 | 0.76 | CHRM5 (0.31) | — | |
| SCHEMBL17359165 | 0.76 | CHRM5 (0.31) | — | |
| SCHEMBL19853769 | 0.73 | TSHR (0.44) | TSHRAPEX1BLMOPRM1OPRL1 | |
| SCHEMBL15937141 | 0.73 | PIK3CD (0.39) | — | |
| SCHEMBL15937245 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127430-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127430-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | TSHR 1558/4885APEX1 4074/4885BLM 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.